A recent study presented at hashtag#ASH2024 explores the mechanistic insights and clinical implications of a widely prevalent GRK5 variant affecting platelet function. featuring Yanki Yarman, this research highlights how the rs10886430 variant is associated with increased thrombin-induced platelet hyperactivity, potentially elevating the risk of stroke, pulmonary embolism, and coronary artery disease in millions of individuals.
Through genetic screening, preclinical models, and platelet function assays, the team demonstrated that homozygous GRK5 GG carriers exhibit reduced GRK5 protein expression, leading to heightened platelet activation, sustained PAR1 signaling, and greater thrombus formation in vascular injury models. These findings underscore the importance of genetic screening in cardiovascular risk assessment and open the door for targeted therapies to mitigate thrombotic risks.
A huge acknowledgment to Xuefei Zhao, Hyun Sook Ahn, Hannah Thomson, Meghan Roberts, Deborah L. French, Jeffrey Benovic, Timothy Stalker, Mortimer Poncz, and Peisong Ma for their contributions to this pivotal study.
Read more: https://lnkd.in/esqCDnmp
